Skip to main content
Elsevier
View Cart

Books in Pharmaceutical sciences

Elsevier's Pharmaceutical Sciences collection helps pharmaceutical scientists striving to optimize drug design and improve healthcare outcomes by offering comprehensive coverage of every aspect of drug development, integrating disciplines like organic chemistry, biology, and biotechnology. Focused on safety, efficacy, and formulation design, it includes specialized fields such as Clinical Pharmacology and Translational Research, providing valuable insights into the latest advancements in drug discovery.

BooksJournals

    • Advances in Antiviral Drug Design

      • 1st Edition
      • Volume 3
      • November 22, 1999
      • E. De Clercq
      • English
      • Paperback
        9 7 8 0 4 4 4 5 4 3 6 0 8
      • Hardback
        9 7 8 0 7 6 2 3 0 2 0 1 7
      • eBook
        9 7 8 0 0 8 0 5 2 6 0 4 1
      Volume 3 of Advances in Antiviral Drug Design is keeping up with the recent progress made in the field of antiviral drug research and highlights five specific directions that have opened new avenues for the treatment of virus infections. First, the use of lamivudine (3TC) for the treatment of HIV infections, and its more recent introduction for the treatment of hepatitis B virus (HBV) infections, has heralded the transition of D- to L-nucleosides in the antiviral nucleoside drug design, and it is likely that the future will provide more nucleosides of the L-configuration, such as (-)FFC (emtricitabine) and L-FMAU, as will be described by J.-C.G. Graciet and R.F. Shinazi. Second, the acyclic purine nucleoside phosphonates, i.e. PMEA (adefovir and PMPA (tenofovir), offer great potential as both anti-HIV and anti-HBV agents, and both compounds have been the subject of advanced clinical trials in their oral produrg form (adefovir dipivoxil and tenofovir disoproxyl), as mentioned by M.N. Arimilli, J.P. Dougherty, K.C. Cundy, and N. Bischofberger.Third, with the advent of nevirapine, delavirdine, and efavirenz, the NNRTIs have definitely come of age. Emivirine (MKC-442), a derivative of the original HEPT analog that was described in 1989 has now proceeded through pivotal clinical studies, and how this class of compounds evolved is presented in the account of H. Tanaka and his colleagues. Fourth, at the end of 1999, anticipating on the next winter influenza offensive, we should have at end two compounds that specifically inhibit influenza A and B virus infections: zanamivir (by the intranasal route) and oseltamivir (by the oral route). Both compounds have proved effective in the prophylaxis and treatment of influenza A and B virus infections and act through the same mechanism; that is by blocking the viral neuraminidase (or sialidase), a key enzyme that allows the virus to spread from one cell to another (within the respiratory mucosal tract). The design of these sialidase inhibitors will be presented by M. von Itzstein and J.C. Dyason.Fifth, the discovery (in 1996) of the chemokine receptors CXCR4 and CCR5 as essential coreceptors (in addition to the CD4 receptor) for HIV entry into the cells, has boosted an enormous interest in potential antagonists of these receptors. The bicyclams represent the first low-molecular-weight compounds targeted at CXCR4, the coreceptor used by the more pathogenic, T-lymphotropic, HIV strains, to enter the cells. They will be addressed by G.J. Bridger and R.T. Skerlj.The five topics covered in this third volume of Advances in Antiviral Drug Design are in the front line of the present endeavors towards the chemotherapy of virus infections. They pertain to the combat against three of the most important virus infections of current times: HIV, HBV, and influenza virus.

    • Analytical Profiles of Drug Substances and Excipients

      • 1st Edition
      • Volume 26
      • October 5, 1999
      • English
      • Paperback
        9 7 8 0 1 2 3 9 1 8 0 4 8
      • Hardback
        9 7 8 0 1 2 2 6 0 8 2 6 1
      • eBook
        9 7 8 0 0 8 0 8 6 1 2 1 0
      Although the official compendia define a drug substance as to identity, purity, strength, and quality, they normally do not provide other physical or chemical data, nor do they list methods of synthesis or pathways of physical or biological degradation and metabolism. Such information is scattered throughout the scientific literature and the files of pharmaceutical laboratories. Edited by the Associate Director of Analytical Research and Development for the American Association of Pharmaceutical Scientists, Analytical Profiles of Drug Substances and Excipients brings this information together into one source. The scope of the series has recently been expanded to include profiles of excipient materials.

    • Advances in Pharmacology

      • 1st Edition
      • Volume 46
      • May 5, 1999
      • English
      • Paperback
        9 7 8 0 1 2 3 9 1 7 6 0 7
      • Hardback
        9 7 8 0 1 2 0 3 2 9 4 7 2
      • eBook
        9 7 8 0 0 8 0 5 8 1 3 8 5
      Each volume of Advances in Pharmacology provides a rich collection of reviews on timely topics. Emphasis is placed on the molecular bases of drug action, both applied and experimental.

    • Advances in Medicinal Chemistry

      • 1st Edition
      • Volume 4
      • April 1, 1999
      • B.E. Maryanoff + 1 more
      • English
      • Hardback
        9 7 8 0 7 6 2 3 0 0 6 4 8
      • Paperback
        9 7 8 0 4 4 4 5 4 6 4 9 4
      • eBook
        9 7 8 0 0 8 0 5 2 6 3 7 9
      Volume 4 of Advances in Medicinal Chemistry is comprised of six chapters on a wide range of topics in medicinal chemistry, including molecular modeling, structure-based drug design, organic synthesis, peptide conformational analysis, biological assessment, structure-activity correlation, and lead optimization. Chapter 1 presents an account about amino acid-based peptide mimetics corresponding to b-turn, loop, helical motifs in proteins as a probe of ligand-receptor and ligand-enzyme molecular interactions. Chapter 2 addresses new facets of the medicinal chemistry of the important anticancer drug Taxol® (paclitaxel). Chapter 3 relates an account of the search for new drugs for the treatment of malaria based on the natural product artemisinin. Chapter 4 applies computational chemistry to the evaluation of compound libraries for biological testing. Chapter 5 describes the construction of a 3-dimensional molecular model of the human thrombin receptor, the first protease-activated G-protein coupled receptor (PAR-1), as a means to explore the intermolecular contacts involved in agonist peptide recognition. Finally, Chapter 6 describes the research conducted at Merck on inhibitors of farnesyl transferase as a potential treatment for human cancers.

    • Medical Applications of Liposomes

      • 1st Edition
      • July 22, 1998
      • D.D. Lasic + 1 more
      • English
      • Hardback
        9 7 8 0 4 4 4 8 2 9 1 7 7
      • eBook
        9 7 8 0 0 8 0 5 3 6 0 8 8
      The development of liposomes as a drug delivery system has fluctuated since its introduction in the late 1960's by A.D. Bangham. While academic research of liposomes as a model membrane system has always flourished, as the exponential growth of papers can testify, the application of these findings to medically useful products has gone through several crises. Following the original optimism in the 70's and early 80's, a period of severe skepticism ensued at the end of the 80's and beginning of the 90's, culminating in a moderate but real optimism in the mid 90's, as a result of a successful launch of the first products in the US and Europe.In this collection of papers, the editors have gathered the most promising ideas, approaches, applications and commercial developments, thereby presenting an up-to-date compilation of the present status of the field. This includes such broad areas as anti-cancer chemotherapy immune stimulation and infectious diseases. Currently, the major areas of progress are in delivery of anti-fungal agents by conventional liposomes or lipid-based carriers and systemic anticancer therapy using long-circulating liposomes. The future applications as characterized by the direction of present day research is in specific targeting and delivery of informational molecules such as DNA plasmids (genes), antisense oligonucleotides or ribozymes. Other future developments may be in topical delivery, vaccination and in diagnostics.Features of this book:• Contributions from almost all the leading labs in the field• Up-to-date, critical reviews bridged by editors' introductions• Organized into a logical framework.

    • The Many Faces of RNA

      • 1st Edition
      • December 19, 1997
      • D. S. Eggleston + 2 more
      • English
      • Hardback
        9 7 8 0 1 2 2 3 3 2 1 0 4
      • Paperback
        9 7 8 0 1 2 3 9 0 9 2 5 1
      • eBook
        9 7 8 0 0 8 0 5 4 2 5 5 3
      The Many Faces of RNA is the subject for the eighth SmithKline Beecham Pharmaceuticals Research Symposia. It highlights a rapidly developing area of scientific investigation. The style and format are deliberately designed to promote in-depth presentations and discussions and to facilitate the forging of collaborations between academic and industrial partners.This symposium focuses on several of the many fundamental, advancing strategies for exploring RNA and its functions. It emphasizes the interplay between biology, chemistry, genomics, and molecular biology which is leading to exciting new insights and avenues of investigation. The book explores RNA as a therapeutic target, RNA as a tool, RNA and its interactions, along with chemical, computational, and structural investigations.

    • Approaches to Design and Synthesis of Antiparasitic Drugs

      • 1st Edition
      • Volume 25
      • July 10, 1997
      • N. Anand + 1 more
      • English
      • Paperback
        9 7 8 0 4 4 4 5 5 1 3 5 1
      • Hardback
        9 7 8 0 4 4 4 8 9 4 7 6 2
      • eBook
        9 7 8 0 0 8 0 5 2 7 5 2 9
      This book presents a comprehensive and up to date account of the chemotherapy of parasitic diseases, both human and veterinary. The book starts with an overview of parasitic diseases. The body of the book is divided into two parts: antihelminthic drugs, and antiprotozoal drugs. Both parts start with chapters highlighting the 'biochemical targets' available for chemotherapeutic interference. Individual chapters deal with one chemical class of compounds and describe their origin, structure-activity relationship, mode of action, and methods of synthesis and their status both in clinical and veterinary practice. The book will be useful to a wide spectrum of readers: students embarking on a research career in parasitic chemotherapy, clinicians (and veterinarians) and clinical pharmacologists desiring detailed information about the drugs currently in use, and pharmaceutical technologists wanting to update their knowledge of the methods of manufacture.

    • Advances in Pharmacology

      • 1st Edition
      • Volume 37
      • September 30, 1996
      • English
      • Paperback
        9 7 8 0 1 2 3 9 9 3 6 4 9
      • Hardback
        9 7 8 0 1 2 0 3 2 9 3 8 0
      • eBook
        9 7 8 0 0 8 0 5 8 1 2 9 3
      Each volume of Advances in Pharmacology provides a rich collection of reviews on timely topics. Emphasis is placed on the molecular bases of drug action, both applied and experimental.

    • Advances in Drug Research

      • 1st Edition
      • Volume 28
      • July 2, 1996
      • English
      • Hardback
        9 7 8 0 1 2 0 1 3 3 2 8 4
      • eBook
        9 7 8 0 0 8 0 5 2 6 7 1 3
      This volume continues the trend for Advances in Drug Research of shorter, but more frequent volumes. In line with the tradition of the series, chapters on general themes are interspersed with chapters on specific drug classes and targets.

    • Advances in Antiviral Drug Design

      • 1st Edition
      • Volume 2
      • April 23, 1996
      • E. De Clercq
      • English
      • Paperback
        9 7 8 0 4 4 4 5 4 1 6 9 7
      • eBook
        9 7 8 0 0 8 0 5 2 6 0 3 4
      The purpose of the series on Advances in Antiviral Drug Design is to regularly review the "state of the art" on emerging new developments in the antiviral drug research field, thereby spanning the conceptual design and chemical synthesis of new antiviral compounds, their structure-activity relationship, mechanism and target(s) of action, pharmacological behavior, antiviral activity spectrum, and therapeutic potential for clinical use. Volume 2 begins with a description of the antiviral potential of antisense oligonucleotides by J. Temsamani and S. Agrawal. According to the aims of the anitsense technology, these oligonucleotides should be targeted at specific viral antisense technology, these oligonucleotides should be targeted at specific viral mRNA sequences so that translation to the virus-specified proteins is blocked; this has been achieved for a number of oligomers, some of which are now in clinical trials for the treatment of HIV, HCMV, and human papilloma virus (HPV) infections. Then C.-S. Yuan, S. Liu, S.F. Wnuk, M.J. Robins and R.T. Borchardt assess the role of S-adenosylhornocyste... (AdoHcy) hydrolase as target for the design of antiviral agents with broad-spectrum antiviral activity. This is followed by an in-depth account on the design and synthesis of a number of first-, second- and third-generation AdoHcy hydrolase inhibitors and their mode of action at the enzyme level.V.E. Marquez provides a comprehensive description of the various carbocyclic (carba) nucleosides that have been synthesized and evaluated for antiviral activity. Although the number and diversity of the carba-nucleosides that have been found to be antivirally active (or inactive) is astonishingly high, there is no limit to further expansion of this fascinating class of molecules. For the various nucleoside analogues that have to be intracellularly phosphorylated to the 5'-triphosphate stage, to interact with their target enzyme (i.e., herpesviral DNA polymerase or retroviral revers transcriptase) the first phosphorylation step is often the rate-limiting step, and thus various strategies are envisaged by C. Perigoud, J.-L. Girardet, G. Gosselin and J.-L. Bach on how to bypass this initial phosphorylation and to deliver the nucleoside 5'-monophophate directly inside the cells.The HIV protease has been considered as a paradigm for rational drug design. The enzyme is among the best understood in terms of both structure and action, and because of its crucial role in the maturation of HIV, it has been vigorously pursued as a target for anti-HIV chemotherapy. In their comprehensive review of the multidisciplinary approach towards the development of HIV protease inhibitors A.G. Tomasselli, S. Thaisrivongs and R.L. Heinrikson highlight those protease inhibitors which have been brought forward to clinical trials.

Related subjects

Drug delivery

Drug design

Drug dispensing

Drug manufacturing and packaging

Drug metabolism disposition

Pharmaceutical analysis

Pharmaceutical biotechnology

Pharmaceutical quality control

Pharmaceutical science general

Pharmaceutical technology

Pharmacoeconomics

Pharmacoepidemiology

Pharmacotherapy

Pharmacy

Pharmacy management